Key facts
as of Sep 2026- Treeline Biosciences’s last known valuation is $1.3B (Oct 2022).
- It has raised $1.1B across 2 recorded rounds; the latest was Later Stage VC ($200.1M) in Aug 2025.
- Notable investors include GV, OrbiMed, ARCH Venture Partners, T. Rowe Price Group, Fidelity — 14 tracked in total.
- 2 institutional filers report fund marks on Treeline Biosciences across 15 filings.
- Treeline Biosciences has filed 2 Form Ds with the SEC since 2024, most recently Sep 2025 ($200.1M sold to 22 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Treeline Biosciences
Recorded secondary trades
No secondary trades in Treeline Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest Apr 20262 SEC-registered funds reported 15 fair-value marks on Treeline Biosciences between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
2 roundsAbout Treeline Biosciences
Developer of transformative precision medicines intended to treat cancer and other serious conditions. The company's platform is involved in assessments of normal and disease pathophysiology, experimental results, genomics, and pattern recognition to develop transformative precision addressing unmet patient needs, enabling medical professionals to cure cancer and other serious conditions.
- Sector
- Healthcare
- HQ
- Watertown, MA, United States
- Founded
- 2021
- Employees
- 149
- Website
- treeline.bio/
- Ownership
- Privately Held (backing)